Overexpression of cathepsin K and vascular endothelial growth factor in chronic venous ulcerations
Paweł Kolano, Igor A Bednarski, Aleksandra Lesiak, Małgorzata Skibińska, Olga Stasikowska-Kanicka, Marian Danilewicz, Joanna Narbutt, Paweł Kolano, Igor A Bednarski, Aleksandra Lesiak, Małgorzata Skibińska, Olga Stasikowska-Kanicka, Marian Danilewicz, Joanna Narbutt
Abstract
Introduction: Chronic venous disease (CVD) is a disabling condition affecting about 1% to 3% of the general population. Besides varicose veins, CVD can result also in the formation of severe skin lesions, especially venous ulcerations (VU). The exact mechanism of VU is still unknown.
Aim: To evaluate immunoexpression of vascular endothelial growth factor (VEGF) and cathepsin K in healthy individuals and patients with VU.
Material and methods: The study included 12 patients with venous ulcers and 10 healthy individuals who served as controls; both groups were sex- and age-matched. Biopsy samples were obtained from lower leg areas and submitted to histochemical analysis.
Results: There was a significant difference between the study group and the control group in cathepsin K expression (1.007 ±0.3 vs. 0.22 ±0.2, respectively, p < 0.001) and VEGF expression (1.17 ±0.59 vs. 0.27 ±0.19, respectively, p < 0.001). Additionally, the microvessel density (per mm2) differed significantly between the study group and the control group (97.6 ±28.81 vs. 59.32 ±12.71, respectively, p < 0.001). We found no correlation between cathepsin K and microvessel density, and cathepsin K and VEGF in both groups, but there was a significant correlation between microvessel density and VEGF immunoexpression in the study group (r = 0.82, p = 0.002).
Conclusions: Increased immunoexpression of VEGF and cathepsin K suggests that both of these proteins may play a role in VU development.
Keywords: cathepsin K; immunohistochemistry; venous ulceration.
Conflict of interest statement
The authors declare no conflict of interest.
Copyright: © 2020 Termedia Sp. z o. o.
Figures
References
- Raffetto JD. Pathophysiology of chronic venous disease and venous ulcers. Surg Clin North Am. 2018;98:337–47.
- Fowkes FGR, Evans CJ, Lee AJ. Prevalence and risk factors of chronic venous insufficiency. Angiology. 2001;52:S5–15.
- Peart J. Influence of psychosocial factors on coping and living with a venous leg ulcer. Br J Commun Nurs. 2015;20:S21–7.
- Serra R, Buffone G, Falcone D, et al. Chronic venous leg ulcers are associated with high levels of metalloproteinases-9 and neutrophil gelatinase-associated lipocalin. Wound Repair Regen. 2013;21:395–401.
- Norgauer J, Hildenbrand T, Idzko M, et al. Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers. Br J Dermatol. 2002;147:1180–6.
- Bossard MJ, Tomaszek TA, Thompson SK, et al. Proteolytic activity of human osteoclast cathepsin K. Expression, purification, activation, and substrate identification. J Biol Chem. 1996;271:12517–24.
- Arman A, Bereket A, Coker A, et al. Cathepsin K analysis in a pycnodysostosis cohort: demographic, genotypic and phenotypic features. Orphanet J Rare Dis. 2014;9:60.
- Rao Q, Wang Y, Xia QY, et al. Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions. Int J Clin Exp Pathol. 2014;7:1132–9.
- Ishida M, Kojima F, Okabe H. Cathepsin K expression in basal cell carcinoma. J Eur Acad Dermatology Venereol. 2013;27:e128–30.
- Verbovšek U, Motaln H, Rotter A, et al. Expression analysis of all protease genes reveals cathepsin K to be overexpressed in glioblastoma. PLoS One. 2014;9:e111819.
- Bühling F, Röcken C, Brasch F, et al. Pivotal role of cathepsin K in lung fibrosis. Am J Pathol. 2004;164:2203–16.
- Chilosi M, Pea M, Martignoni G, et al. Cathepsin-K expression in pulmonary lymphangioleiomyomatosis. Mod Pathol. 2009;22:161–6.
- Hua Y, Xu X, Shi GP, et al. Cathepsin K knockout alleviates pressure overload-induced cardiac hypertrophy. Hypertension. 2013;61:1184–92.
- Li X, Li Y, Jin J, et al. Increased serum cathepsin K in patients with coronary artery disease. Yonsei Med J. 2014;55:912–9.
- Golovatch P, Mercer BA, Lemaître V, et al. Role for cathepsin K in emphysema in smoke-exposed guinea pigs. Exp Lung Res. 2009;35:631–45.
- Sage J, De Quéral D, Leblanc-Noblesse E, et al. Differential expression of cathepsins K, S and V between young and aged Caucasian women skin epidermis. Matrix Biol. 2014;33:41–6.
- Ciążyńska M, Bednarski IA, Wódz K, et al. Impact of ultraviolet radiation on expression of transforming growth factor beta, Smad2, metalloproteinases-1, -3, -8, -9, cathepsin K and progerin. Photochem Photobiol. 2018;94:362–9.
- Rünger TM, Quintanilla-Dieck MJ, Bhawan J. Role of cathepsin K in the turnover of the dermal extracellular matrix during scar formation. J Invest Dermatol. 2007;127:293–7.
- Hirai T, Kanda T, Sato K, et al. Cathepsin K is involved in development of psoriasis-like skin lesions through TLR-dependent Th17 activation. J Immunol. 2013;190:4805–11.
- Kim DD, Kleinman DM, Kanetaka T, et al. Rapamycin inhibits VEGF-induced microvascular hyperpermeability in vivo. Microcirculation. 2010;17:128–36.
- Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13:871–82.
- Demidova-Rice TN, Hamblin MR, Herman IM. Acute and impaired wound healing: pathophysiology and current methods for drug delivery, part 2: role of growth factors in normal and pathological wound healing: therapeutic potential and methods of delivery. Adv Skin Wound Care. 2012;25:349–70.
- Gupta N, Mansoor S, Sharma A, et al. Diabetic retinopathy and VEGF. Open Ophthalmol J. 2013;7:4–10.
- Jiang H, Wu Cheng X, Shi GP, et al. Cathepsin K-mediated notch1 activation contributes to neovascularization in response to hypoxia. Nat Commun. 2014;5:3838.
- Rünger TM, Quintanilla-Dieck MJ, Bhawan J. Role of cathepsin K in the turnover of the dermal extracellular matrix during scar formation. J Invest Dermatol. 2007;127:293–7.
- Bitu CC, Kauppila JH, Bufalino A, et al. Cathepsin K is present in invasive oral tongue squamous cell carcinoma in vivo and in vitro. PLoS One. 2013;8:e70925.
- Quintanilla-Dieck MJ, Codriansky K, Keady M, et al. Expression and regulation of cathepsin K in skin fibroblasts. Exp Dermatol. 2009;18:596–602.
- Zillmer R, Trøstrup H, Karlsmark T, et al. Duration of wound fluid secretion from chronic venous leg ulcers is critical for interleukin-1alpha, interleukin-1beta, interleukin-8 levels and fibroblast activation. Arch Dermatol Res. 2011;303:601–6.
- Drinkwater SL, Burnand KG, Ding R, Smith A. Increased but ineffectual angiogenic drive in nonhealing venous leg ulcers. J Vasc Surg. 2003;38:1106–12.
- Birkenhauer E, Neethirajan S. A double-edged sword: the role of VEGF in wound repair and chemoattraction of opportunist pathogens. Int J Mol Sci. 2015;16:7159–72.
- Shoab SS, Scurr JH, Coleridge-Smith PD. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction – a pilot study. Eur J Vasc Endovasc Surg. 1999;18:334–8.
- Gohel MS, Windhaber RAJ, Tarlton JF, et al. The relationship between cytokine concentrations and wound healing in chronic venous ulceration. J Vasc Surg. 2008;48:1272–7.
Source: PubMed